Helix BioMedix, Inc. (HXBM)
OTC
Healthcare
Biotechnology
$1.15
▲ +0.00%
Market Cap
$258,414
Sector
Healthcare
Industry
Biotechnology
Beta
1.37
52-Wk Range
1-4.5
CEO
Robin L. Carmichael
Country
US
Currency
USD
Helix BioMedix, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bothell, WA, US. The stock last traded at $1.15, up 0.00% on the session, giving a market capitalisation of $258,414. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of -68.3%. Its beta of 1.37 implies it has historically moved more than the broad market.
Valuation & profitability (TTM)
P/E
-0.47
Price / Sales
0.32
Price / Book
0.17
EV / EBITDA
1.85
Gross margin
99.4%
Operating margin
-73.8%
Net margin
-68.3%
Return on equity
—
Debt / equity
0.00
Current ratio
12.16
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
8
IPO date
1999-03-25
Headquarters
Bothell, WA, US
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company was founded in 1988 and is headquartered in Bothell, WA.
Comparable companies
Helix BioMedix, Inc. is most often compared with the following Healthcare names:
More research on HXBM
Open full interactive analysis & DCF →